Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that inhibiting the JAK-STAT pathway with baricitinib restored cellular homeostasis, delayed senescence, and reduced proinflammatory markers in Hutchinson-Gilford progeria syndrome cell models.

This study observed that Epigallocatechin-3-gallate (EGCG) can inhibit phosphorylation of STAT1 and reduce a specific subset of immune cells in vitro and ex vivo, suggesting a potential role in maintaining immune privilege in alopecia areata.

This study found that IL-6 knockout mice exhibited increased wound-induced hair neogenesis compared to wild-type mice, likely due to enhanced STAT3 activation facilitated by compensatory cytokine activity.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.

This review highlights the potential of ginseng and its metabolites in preventing hair loss, detailing their hair growth-promoting effects observed in numerous preclinical studies, and emphasizing the underlying mechanisms involved.

In this study, topical naringin was found to significantly improve dermatitis severity and reduce inflammatory markers in a mouse model of atopic dermatitis, suggesting its potential as a therapeutic agent for this condition.

This article discusses the clinical and histological features of alopecia areata, a T-cell-mediated autoimmune disorder causing unpredictable nonscarring hair loss, without providing new clinical findings.

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

This review examines targeting the JAK-STAT pathway in inflammatory skin diseases, highlighting existing JAK inhibitors and potential developments, but presents no new experimental or clinical results.

Alopecia totalis/universalis involves more intense immune activity and inflammation than patchy alopecia areata.

Lasheras-Pérez et al. reported that JAK3 and TYK2 proteins are activated in certain forms of primary cicatricial alopecia, suggesting the JAK/TYK/STAT pathway as a potential therapeutic target for these conditions.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

In this study, the researchers using Shh-GFP^+/- mice found that cyclophosphamide-induced alopecia involves the JAK/STAT1 pathway, where STAT1 binds the Shh gene promoter, decreasing Shh-expressing cells in hair follicles. Treatment with JAK inhibitors helped rescue hair loss, implicating the JAK/STAT1 pathway in this process.

This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.

This systematic review assessed the off-label use of topical Ruxolitinib cream for various skin conditions and found it effective for lichenoid and granulomatous dermatoses, though results for alopecia areata were inconsistent. The authors indicate that further research is warranted to confirm these findings.

This review reports that the compound Cepharanthine shows promise as a cancer therapy by inducing cell death, arresting cell growth, inhibiting tumor progression, modulating key oncogenic pathways, and reversing multidrug resistance, suggesting its potential for further investigation in oncology.

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

In this study on testosterone-induced benign prostatic hyperplasia in rats, hydroxychloroquine significantly reduced prostate-related markers and enhanced therapeutic effects when combined with finasteride, suggesting potential as a new treatment approach.

This study found that STAT5 activation in the dermal papilla acts as a key switch to trigger anagen entry in postdevelopmental hair follicle cycling.

This study found that 3-Deoxysappanchalcone may stimulate hair growth in mice by promoting proliferation of hair follicle dermal papilla cells through WNT/β-catenin and STAT signaling modulation.